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BACKGROUND
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with 
tamoxifen, in postmenopausal women with hormone-receptor–positive breast cancer.
METHODS
In two phase 3 trials, we randomly assigned premenopausal women with hormone-
receptor–positive early breast cancer to the aromatase inhibitor exemestane plus 
ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. 
Suppression of ovarian estrogen production was achieved with the use of the go-
nadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irra-
diation. The primary analysis combined data from 4690 patients in the two trials. 
RESULTS
After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% 
in the exemestane–ovarian suppression group and 87.3% in the tamoxifen–ovarian 
suppression group (hazard ratio for disease recurrence, second invasive cancer, or 
death, 0.72; 95% confidence interval [CI], 0.60 to 0.85; P<0.001). The rate of free-
dom from breast cancer at 5 years was 92.8% in the exemestane–ovarian suppres-
sion group, as compared with 88.8% in the tamoxifen–ovarian suppression group 
(hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P<0.001). With 194 deaths 
(4.1% of the patients), overall survival did not differ significantly between the two 
groups (hazard ratio for death in the exemestane–ovarian suppression group, 1.14; 
95% CI, 0.86 to 1.51; P = 0.37). Selected adverse events of grade 3 or 4 were reported 
for 30.6% of the patients in the exemestane–ovarian suppression group and 29.4% 
of those in the tamoxifen–ovarian suppression group, with profiles similar to those 
for postmenopausal women.
CONCLUSIONS
In premenopausal women with hormone-receptor–positive early breast cancer, 
adjuvant treatment with exemestane plus ovarian suppression, as compared with 
tamoxifen plus ovarian suppression, significantly reduced recurrence. (Funded by 
Pfizer and others; TEXT and SOFT ClinicalTrials.gov numbers, NCT00066703 
and NCT00066690, respectively.)
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The most effective adjuvant endo-crine therapy for premenopausal women with hormone-receptor (estrogen, proges-
terone, or both)–positive breast cancer is uncer-
tain. Tamoxifen for at least 5 years is a standard 
of care.1-3 Adjuvant suppression of ovarian function 
(hereafter, ovarian suppression) may be recom-
mended in addition. For postmenopausal wom-
en, adjuvant therapy with an aromatase inhibitor, 
as compared with tamoxifen, improves outcomes.2-9
In 2003, the International Breast Cancer Study 
Group (IBCSG) initiated two randomized, phase 3 
trials, the Tamoxifen and Exemestane Trial (TEXT) 
and the Suppression of Ovarian Function Trial 
(SOFT), involving premenopausal women with 
hormone-receptor–positive early breast cancer, 
through collaboration with the Breast Interna-
tional Group (BIG) and the North American Breast 
Cancer Group. The trials were designed to deter-
mine whether adjuvant therapy with the aromatase 
inhibitor exemestane improved disease-free sur-
vival, as compared with tamoxifen, among pre-
menopausal women treated plus ovarian sup-
pression and to determine the value of ovarian 
suppression in women who were suitable candi-
dates for treatment with adjuvant tamoxifen. Here 
we report the results of the planned10 primary 
combined analysis of data from TEXT and SOFT 
comparing adjuvant exemestane plus ovarian sup-
pression with adjuvant tamoxifen plus ovarian 
suppression after a median follow-up of 68 months.
ME THODS
PATIENTS
Eligibility in each trial required documented pre-
menopausal status. Inclusion criteria were histo-
logically proven operable breast cancer confined 
to the breast and ipsilateral axilla, with the excep-
tion of internal-mammary-node involvement de-
tected by means of sentinel-node biopsy, and tumor 
that expressed estrogen or progesterone receptors 
in at least 10% of the cells, as assessed with the 
use of immunohistochemical testing. Patients with 
synchronous bilateral hormone-receptor–positive 
breast cancer were eligible. Patients had under-
gone either a total mastectomy with subsequent 
optional radiotherapy or breast-conserving sur-
gery with subsequent radiotherapy. Either axillary 
dissection or a negative sentinel-node biopsy was 
required. Macrometastasis in a sentinel node re-
quired axillary dissection or irradiation.
All the patients in TEXT and the patients in 
SOFT who did not receive chemotherapy under-
went randomization within 12 weeks after de-
finitive surgery; patients in SOFT who received 
adjuvant or neoadjuvant chemotherapy underwent 
randomization within 8 months after complet-
ing chemotherapy, once a premenopausal level 
of estradiol was confirmed. Consistent with this 
design, patients in SOFT, but not those in TEXT, 
were allowed to receive adjuvant oral endocrine 
therapy before randomization.
STUDY DESIGNS
TEXT was designed to evaluate 5 years of therapy 
consisting of exemestane plus the gonadotropin-
releasing-hormone (GnRH) agonist triptorelin ver-
sus tamoxifen plus triptorelin in women who re-
ceived ovarian-suppression therapy from the start 
of adjuvant therapy. Eligible women were ran-
domly assigned in a 1:1 ratio to receive oral ex-
emestane (Aromasin, Pfizer), at a dose of 25 mg 
daily, plus triptorelin (Decapeptyl Depot [trip-
torelin acetate], Ipsen; or Trelstar Depot [trip-
torelin pamoate], Debio), at a dose of 3.75 mg 
administered by means of intramuscular injec-
tion every 28 days, or oral tamoxifen at a dose of 
20 mg daily plus triptorelin. Bilateral oophorec-
tomy or ovarian irradiation was allowed after at 
least 6 months of triptorelin.
Chemotherapy was optional in TEXT, and if 
administered, was started concomitantly with 
triptorelin; oral endocrine therapy was started 
after the completion of chemotherapy. If chemo-
therapy was not administered, oral endocrine 
therapy was started 6 to 8 weeks after the initia-
tion of triptorelin, to allow for a decline in ovar-
ian estrogen production. Randomization to open-
label treatment was performed by means of the 
IBCSG Internet-based system, with the use of 
permuted blocks, and was stratified according 
to the intended use of adjuvant chemotherapy 
(yes vs. no) and lymph-node status (negative vs. 
positive).
SOFT was designed to evaluate 5 years of ex-
emestane plus ovarian suppression versus tamox-
ifen plus ovarian suppression versus tamoxifen 
alone in women who remained premenopausal 
after the completion of adjuvant or neoadjuvant 
chemotherapy or in women for whom adjuvant 
tamoxifen alone was suitable treatment. Eligible 
women were randomly assigned in a 1:1:1 ratio 
to exemestane plus ovarian suppression (trip-
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torelin, bilateral oophorectomy, or ovarian irra-
diation), tamoxifen plus ovarian suppression, or 
tamoxifen alone. Randomization was stratified 
according to prior use of adjuvant or neoadjuvant 
chemotherapy (yes vs. no), lymph-node status 
(negative vs. positive), and intended initial meth-
od of ovarian suppression, if the woman was 
assigned to a group that included ovarian-sup-
pression therapy.
In TEXT and SOFT, protocol-assigned endo-
crine therapy continued for 5 years from the date 
of randomization, and the protocols (available 
with the full text of this article at NEJM.org) did 
not address the issue of extended adjuvant endo-
crine therapy beyond 5 years, except the require-
ment to record any therapy. Bisphosphonates 
were not permitted unless indicated for reduced 
bone density (T score, −1.5 or lower) or required 
for participation in a randomized trial of adjuvant 
bisphosphonate therapy. Adjuvant trastuzumab 
was allowed. Patient assessments, recording of 
adverse events, and quality-of-life self-assessments 
followed a regular schedule (see the Supplemen-
tary Appendix, available at NEJM.org).
The primary end point was disease-free sur-
vival, defined as the time from randomization to 
the first appearance of one of the following: inva-
sive recurrence of breast cancer (local, regional, 
or distant), invasive contralateral breast cancer, 
second (nonbreast) invasive cancer, or death with-
out breast-cancer recurrence or second invasive 
cancer. Secondary end points included the follow-
ing: time interval without breast cancer, defined 
as the time from randomization to the recur-
rence of invasive breast cancer (local, regional, or 
distant) or invasive contralateral breast cancer; 
time interval before a recurrence of breast can-
cer at a distant site, defined as the time from 
randomization to the recurrence of breast cancer 
at a distant site; and overall survival, defined as 
the time from randomization to death from any 
cause. For patients who did not have an end-point 
event, the times were censored at the date of the 
last follow-up visit (or for the analysis of overall 
survival, the date at which the patient was last 
known to be alive).
STUDY OVERSIGHT
TEXT (IBCSG trial number 25-02) and SOFT 
(IBCSG trial number 24-02) were coordinated by 
the IBCSG, which was responsible for the study 
designs, randomization, collection and manage-
ment of data, medical review, data analysis, and 
reporting. The ethics committee at each partici-
pating center approved the study protocols, and 
all the patients provided written informed con-
sent. The IBCSG data and safety monitoring com-
mittee reviewed safety data semiannually.
Pfizer and Ipsen, the respective manufacturers 
of exemestane and triptorelin, donated the study 
drugs; neither manufacturer imposed restrictions 
with respect to the trial data. The manuscript 
was written solely by the authors, who vouch for 
the data and analyses reported and for the fidelity 
of the study to the protocol. The steering com-
mittee (which included employees of Pfizer and 
Ipsen) reviewed the manuscript and were respon-
sible for the decision to submit it for publication.
STATISTICAL ANALYSIS
The original statistical analysis plans for TEXT 
and SOFT were to compare disease-free survival 
between treatment groups within each trial sepa-
rately, with a planned secondary combined analy-
sis of exemestane plus ovarian suppression versus 
tamoxifen plus ovarian suppression. However, the 
patients enrolled in the studies had lower-risk 
characteristics than had been anticipated in the 
design assumptions, and the rate of disease-free 
survival was better than expected. To ensure 
timely answers to the trial questions, protocol 
amendments to the analysis plans were adopted 
in 2011, designating the combined analysis of 
data from TEXT and SOFT as the primary analy-
sis of exemestane plus ovarian suppression ver-
sus tamoxifen plus ovarian suppression. The 
comparison of tamoxifen plus ovarian suppres-
sion versus tamoxifen alone in SOFT, to deter-
mine the value of adding ovarian suppression to 
tamoxifen, has not been analyzed and is not part 
of the present report.
We calculated that, with an estimated 436 
events of disease recurrence, second invasive 
cancer, or death by the third quarter of 2013, the 
study would have at least 84% power to detect a 
hazard ratio of 0.75 with exemestane plus ovar-
ian suppression versus tamoxifen plus ovarian 
suppression in the primary combined analysis, 
at a two-sided alpha level of 0.05. The original 
statistical designs and sample-size assumptions 
and the amended plans have been described 
previously.10 The steering committee proposed, 
and the data and safety monitoring committee 
endorsed, the amended analysis plans without 
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knowledge of the data according to treatment as-
signment. No interim analyses were performed.
Analyses were performed according to the in-
tention-to-treat principle. Kaplan–Meier estimates 
of time-to-event end points were calculated. Cox 
proportional-hazards regression analyses and the 
log-rank test, stratified according to trial, receipt 
or no receipt of chemotherapy, and lymph-node 
status, were used to estimate hazard ratios, 95% 
confidence intervals, and P values comparing the 
two groups. The heterogeneity of the treatment 
effect according to subgroup was investigated by 
means of tests of treatment-by-covariate interac-
tion. Quality-of-life data over the 5-year treatment 
period were analyzed as the change from base-
line in quality-of-life indicators, with the use of 
mixed-effects regression modeling. The visit cut-
off date was August 31, 2013, and the database-
lock date for analysis was February 1, 2014.
R ESULT S
STUDY POPULATION
From November 2003 through April 2011, we 
randomly assigned 2359 premenopausal women 
to exemestane plus ovarian suppression and 2358 
to tamoxifen plus ovarian suppression. Two thirds 
of the women were enrolled at BIG centers and 
one third at North American centers. After exclu-
sions, 4690 women were included in the inten-
tion-to-treat population (Fig. 1). The median age 
of the patients at randomization was 43 years 
(Table 1). A total of 42.6% of the patients did not 
receive chemotherapy, and 57.4% received che-
motherapy either after randomization in TEXT 
(34.3% of all patients) or before randomization 
in SOFT (23.2%). Among patients in SOFT who 
had received chemotherapy previously, 41.7% had 
received tamoxifen for an average of 4 months 
before randomization while waiting for premeno-
pausal status to be established or reestablished. 
Node-positive disease was present in 42.2% of 
the patients overall, and in 20.7% and 8.3% of 
the patients in TEXT and SOFT, respectively, who 
did not receive chemotherapy.
EFFICACY
After a median follow-up of 68 months, 514 pa-
tients (11.0%) had disease recurrence or second 
invasive cancer or died. The rate of disease-free 
survival at 5 years was 91.1% (95% confidence 
interval [CI], 89.7 to 92.3) among patients assigned 
to receive exemestane plus ovarian suppression, 
as compared with 87.3% (95% CI, 85.7 to 88.7) 
among those assigned to tamoxifen plus ovarian 
suppression (hazard ratio for recurrence, second 
invasive cancer, or death, 0.72; 95% CI, 0.60 to 
0.85; P<0.001) (Fig. 2A). A total of 60.1% of first 
events involved distant sites, and 13.6% were sec-
ond, nonbreast, invasive cancers (Table S3 in the 
Supplementary Appendix). Prospectively planned 
subgroup analyses did not reveal any striking 
heterogeneity of treatment effects (Fig. S1 in the 
Supplementary Appendix), including in subgroups 
defined according to trial and status with respect 
to chemotherapy (Fig. 3).
At 5 years, 92.8% (95% CI, 91.6 to 93.9) of the 
patients assigned to receive exemestane plus ovar-
ian suppression were free from breast cancer, as 
compared with 88.8% (95% CI, 87.3 to 90.1) of 
those assigned to receive tamoxifen plus ovarian 
suppression (hazard ratio for recurrence, 0.66; 
95% CI, 0.55 to 0.80; P<0.001) (Fig. 2B). Among 
patients who did not receive chemotherapy and 
were assigned to receive exemestane plus ovari-
an suppression, 97.6% of the patients in TEXT 
and 97.5% of those in SOFT remained free from 
breast cancer at 5 years (Fig. S2 in the Supple-
mentary Appendix).
The recurrence of breast cancer at a distant 
site was reported in 325 patients (6.9%), and at 
5 years the rate of freedom from distant recur-
rence was 93.8% (95% CI, 92.7 to 94.8) among 
patients assigned to receive exemestane plus 
ovarian suppression, as compared with 92.0% 
(95% CI, 90.7 to 93.1) among those assigned to 
receive tamoxifen plus ovarian suppression (haz-
ard ratio for recurrence, 0.78; 95% CI, 0.62 to 
0.97; P = 0.02) (Fig. 2C). Among patients who 
received chemotherapy, the rate of freedom from 
distant recurrence at 5 years was 2.6 percentage 
points higher among those who were assigned to 
exemestane plus ovarian suppression than 
among those who were assigned to tamoxifen plus 
ovarian suppression in TEXT and 3.4 percentage 
points higher in SOFT (Fig. S3 in the Supple-
mentary Appendix).
Death was reported in 194 patients (4.1%); 
7 patients died without breast-cancer recurrence 
or second invasive cancer. Overall survival at 
5 years was 95.9% (95% CI, 94.9 to 96.7) among 
patients assigned to exemestane plus ovarian sup-
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pression and 96.9% (95% CI, 96.0 to 97.6) among 
those assigned to tamoxifen plus ovarian suppres-
sion; the difference was not significant (Fig. 2D).
ADVERSE EVENTS
At the median follow-up of 68 months, 30.2% of 
the patients were still receiving some or all pro-
tocol-assigned treatments, 56.1% had completed 
treatment, and 13.7% had stopped all protocol-
assigned treatments early (16.1% of the patients 
in the exemestane–ovarian suppression group and 
11.2% of those in the tamoxifen–ovarian sup-
pression group) (Table S4 in the Supplementary 
Appendix). Targeted adverse events of grade 3 or 
4 were reported in 30.6% of the patients assigned 
to receive exemestane plus ovarian suppression 
and in 29.4% of those assigned to receive tamox-
ifen plus ovarian suppression. The events of grade 
3 or 4 that were reported most frequently were 
hot flushes, musculoskeletal symptoms, and hy-
pertension (Table 2). Depression was reported in 
50.2% of patients, with grade 3 or 4 depression 
in 4.1% of the patients.
Osteoporosis (T score, less than −2.5) was 
reported in 13.2% of the patients assigned to 
exemestane plus ovarian suppression and in 6.4% 
of those assigned to tamoxifen plus ovarian sup-
pression. Fractures, musculoskeletal symptoms, 
2672 Patients underwent randomization
in TEXT
1334 Were assigned to
tamoxifen plus ovarian
suppression
1021 Were assigned to
exemestane plus ovarian
suppression
1024 Were assigned to
tamoxifen plus ovarian
suppression
2358 Were assigned to
tamoxifen plus ovarian
suppression
2359 Were assigned to
exemestane plus ovarian
suppression
1021 Were assigned to
tamoxifen
13 Were excluded from the 
intention-to-treat 
population
2 Had inadequate docu-
mentation of informed
consent
1 Was at a nonadherent
center
10 Withdrew consent
14 Were excluded from the
intention-to-treat 
population
2 Were at a nonadherent
center
12 Withdrew consent
1338 Were assigned to
exemestane plus ovarian
suppression
3066 Patients underwent randomization
in SOFT
2346 Were included in the
intention-to-treat
    population
2318 Started treatment
28 Never started
treatment
124 Withdrew consent
74 Were lost to follow-up
2344 Were included in the
intention-to-treat
    population
2329 Started treatment
15 Never started
treatment
108 Withdrew consent
77 Were lost to follow-up
Figure 1. Randomization, Treatment, and Follow-up.
Of the 383 patients who withdrew consent or were lost to follow-up, 150 consented to the continued submission of disease-recurrence 
and survival status from medical records or such updates are obtainable from tumor and vital registries according to the protocol fol-
low-up schedule. SOFT denotes Suppression of Ovarian Function Trial, and TEXT Tamoxifen and Exemestane Trial.
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vaginal dryness, decreased libido, and dyspareunia 
were reported more frequently in patients assigned 
to exemestane plus ovarian suppression, where-
as thromboembolic events, hot flushes, sweat-
ing, and urinary incontinence were reported 
more frequently in patients assigned to tamoxi-
fen plus ovarian suppression. Gynecologic cancer 
occurred in seven patients assigned to exemestane 
plus ovarian suppression and in nine assigned to 
tamoxifen plus ovarian suppression, including 
endometrial cancers in two and five patients, re-
spectively.
QUALITY OF LIFE
Changes from baseline in global indicators of 
mood, physical well-being, and coping effort 
were similar in the two treatment groups during 
the treatment period. Patients assigned to ex-
emestane plus ovarian suppression reported sig-
nificantly more detrimental effects of bone or 
joint pain and vaginal dryness and a greater loss 
of sexual interest, whereas patients assigned to 
tamoxifen plus ovarian suppression were signifi-
cantly more affected by hot flushes and vaginal 
discharge.12
DISCUSSION
The combined analysis of data from TEXT and 
SOFT shows that among premenopausal women 
with hormone-receptor–positive breast cancer, 
adjuvant endocrine therapy with exemestane plus 
Table 1. Characteristics of Patients in TEXT and SOFT, Overall and According to Trial and Chemotherapy Stratum.*
Characteristic
No-Chemotherapy  
Cohorts
Chemotherapy  
Cohorts†
Overall  
(N = 4690)
TEXT
(N = 1053)
SOFT
(N = 943)
TEXT
(N = 1607)
SOFT
(N = 1087)
Age at randomization — no. (%)
<35 yr 41 (3.9) 14 (1.5) 191 (11.9) 224 (20.6) 470 (10.0)
35–39 yr 123 (11.7) 68 (7.2) 289 (18.0) 312 (28.7) 792 (16.9)
40–49 yr 768 (72.9) 690 (73.2) 1048 (65.2) 515 (47.4) 3021 (64.4)
≥50 yr 121 (11.5) 171 (18.1) 79 (4.9) 36 (3.3) 407 (8.7)
Lymph-node status — no. (%)
Negative 835 (79.3) 865 (91.7) 542 (33.7) 470 (43.2) 2712 (57.8)
Positive 218 (20.7) 78 (8.3) 1065 (66.3) 617 (56.8) 1978 (42.2)
Tumor size — no. (%)‡
≤2 cm 847 (80.4) 800 (84.8) 738 (45.9) 537 (49.4) 2922 (62.3)
>2 cm 203 (19.3) 139 (14.7) 844 (52.5) 508 (46.7) 1694 (36.1)
HER2 positive — no. (%) 54 (5.1) 30 (3.2) 272 (16.9) 211 (19.4) 567 (12.1)
Interval from surgery to randomization  
— mo
Median 1.5 1.8 1.2 8.0 1.6
Interquartile range 1.1–1.9 1.3–2.4 0.9–1.6 5.7–10.1 1.1–2.7
Endocrine therapy before randomization  
— no. (%)§
— 44 (4.7) — 453 (41.7) —
* A more complete summary of characteristics is provided in Table S1 in the Supplementary Appendix. Characteristics 
were well balanced according to treatment assignment (Table S2 in the Supplementary Appendix). The statistical analy-
sis plan did not specify hypothesis testing regarding comparisons between these groups. HER2 denotes human epider-
mal growth factor receptor 2, SOFT Suppression of Ovarian Function Trial, and TEXT Tamoxifen and Exemestane Trial.
† Among patients who received chemotherapy, patients in TEXT received chemotherapy during the trial, and those in 
SOFT had received chemotherapy before enrollment.
‡ Data were missing for 3 patients in TEXT who did not receive chemotherapy, for 4 in SOFT who did not receive chemo-
therapy, for 25 in TEXT who received chemotherapy, and for 42 in SOFT who had received chemotherapy previously.
§ Oral endocrine therapy before randomization was allowed in SOFT while premenopausal status was established or re-
established; it was not allowed in TEXT.
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ovarian suppression, as compared with tamoxi-
fen plus ovarian suppression, significantly im-
proved disease-free survival and lengthened the 
time without breast cancer, and the time without 
distant recurrence. The observed relative reduc-
tion of 28% in the risk of disease recurrence, 
second invasive cancer, or death and the relative 
reduction of 34% in the risk of breast-cancer re-
currence among premenopausal women compare 
favorably with the results of randomized trials of 
adjuvant aromatase inhibitors versus tamoxifen 
in postmenopausal women. With a similar me-
dian follow-up period, the BIG 1-98 and Arimi-
dex, Tamoxifen, Alone or in Combination (ATAC) 
trials showed 19% and 26% reductions, respec-
tively, in the risk of breast-cancer recurrence5,7,13 
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Figure 2. Kaplan–Meier Estimates of Disease-free Survival, Freedom from Recurrence of Breast Cancer, Freedom from Recurrence  
of Breast Cancer at a Distant Site, and Overall Survival after a Median Follow-up of 68 Months, According to Treatment Assignment.
The hazard ratio in Panel A is for disease recurrence, second invasive cancer, or death without breast-cancer recurrence or second inva-
sive cancer. The 5-year values are based on Kaplan–Meier estimates of the time to an event. OS denotes ovarian suppression.
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with aromatase inhibitors, as compared with 
tamoxifen.
In the current analysis, the absolute improve-
ment of 4.0 percentage points in the proportion 
of patients without breast cancer at 5 years with 
exemestane plus ovarian suppression, as compared 
with tamoxifen plus ovarian suppression, reflects 
reductions in local, regional, and contralateral 
events and in distant events. Although local, 
regional, and contralateral breast events are po-
tentially curable, they require treatment and af-
fect patient well-being. The majority (60%) of the 
first events of disease recurrence, second inva-
sive cancer, or death involved the recurrence of 
breast cancer at a distant site. Patients selected 
to receive chemotherapy had, on average, higher-
risk clinicopathologic features (associated with a 
greater risk of recurrence) than did those who 
did not receive chemotherapy. Among patients 
who received chemotherapy, exemestane plus ovar-
ian suppression, as compared with tamoxifen 
plus ovarian suppression, increased the propor-
tion of patients without breast cancer at 5 years 
by 5.5 percentage points in TEXT and by 3.9 per-
centage points in SOFT and the proportion of 
patients without distant recurrence at 5 years by 
2.6 percentage points in TEXT and by 3.4 per-
centage points in SOFT (Fig. S3 in the Supple-
mentary Appendix).
Although there was no significant difference 
in overall survival according to randomized treat-
ment, conclusions are premature at 68 months 
of follow-up in this patient population. Trials 
evaluating 5 years of therapy with an adjuvant 
aromatase inhibitor versus tamoxifen therapy in 
postmenopausal women have shown no signifi-
cant survival advantage after a median follow-up 
of 5 years, with absolute improvements in the 
proportion of patients without breast cancer of 
3.4 percentage points and 2.8 percentage points 
in BIG 1-98 and ATAC, respectively, with the 
adjuvant aromatase inhibitor, as compared with 
tamoxifen.5,7,13
In the Austrian Breast and Colorectal Cancer 
Study Group–12 (ABCSG-12) trial,14 a total of 1803 
premenopausal women with hormone-receptor–
positive breast cancer (5.8% of whom had re-
ceived neoadjuvant chemotherapy) were randomly 
assigned to receive 3 years of adjuvant therapy 
with anastrozole plus ovarian suppression (gose-
relin) or tamoxifen plus ovarian suppression, with 
or without the bisphosphonate zoledronic acid 
administered every 6 months. After a median 
follow-up of 62 months, 186 patients had local 
Tamoxifen–OS BetterExemestane–OS Better
All patients
Cohort
No chemotherapy 
    TEXT
    SOFT
Chemotherapy 
    TEXT
    SOFT
Lymph-node status
Negative
Positive
Hazard Ratio (95% CI)Subgroup
0.54 (0.32–0.92)
0.72 (0.60–0.85)
0.60 (0.45–0.81)
0.79 (0.64–0.98)
0.69 (0.53–0.90)
0.68 (0.38–1.19)
No. of Patients
2346
526
470
806
544
1362
984
2344
527
473
801
543
1350
994
Exemestane–
OS
Tamoxifen–
OS
No. of Patients with Event
216
22
20
93
81
70
146
298
40
30
130
98
115
183
Exemestane–
OS
Tamoxifen–
OS
5-Yr Disease-free
Survival (%)
91.1
96.1
95.8
89.8
84.3
95.1
85.6
87.3
93.0
93.1
84.6
80.6
91.6
81.4
Exemestane–
OS
Tamoxifen–
OS
0.50 2.001.00 4.00
0.84 (0.62–1.13)
0.25
Figure 3. Results of the Cox Proportional-Hazards Model for the Comparison of Disease-free Survival, According to Treatment Group, 
among All Patients and According to Patient Cohort.
The solid vertical line at 0.72 indicates the overall hazard-ratio estimate. The x axis is scaled according to the natural logarithm of the 
hazard ratio. The size of the squares is inversely proportional to the standard error of the hazard ratio. Among patients who received 
chemotherapy, the patients in TEXT began receiving chemotherapy concurrently with adjuvant ovarian suppression with triptorelin, 
whereas those in SOFT had completed all chemotherapy before enrollment.
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or regional recurrence, cancer in the contralat-
eral breast, distant metastasis, or second pri-
mary carcinoma or died from any cause, with no 
significant difference in the rate of disease-free 
survival between patients who received anastro-
zole plus ovarian suppression and those who 
received tamoxifen plus ovarian suppression 
(hazard ratio for disease progression or death, 
1.08; 95% CI, 0.81 to 1.44).
The difference between the results of the 
ABCSG-12 trial and the results of the TEXT and 
SOFT trials may relate to greater statistical power 
in the combined analysis of TEXT and SOFT 
(with three times the number of events of dis-
ease recurrence, second invasive cancer, or death 
in TEXT and SOFT as in the ABCSG-12 trial), to 
different treatment durations, or to both. The 
3-year duration of aromatase inhibitor therapy in 
the ABCSG-12 trial may have been insufficient, 
as compared with 3 years of tamoxifen, which is 
known to exert a carryover effect after the ces-
sation of treatment.15 A difference in the efficacy 
of the aromatase inhibitors is unlikely, given the 
absence of a difference observed in postmeno-
pausal women in the MA.27 trial.16 The ABCSG-12 
trial showed a lower rate of overall survival with 
anastrozole plus ovarian suppression than with 
tamoxifen plus ovarian suppression (hazard ra-
tio for death, 1.75; 95% CI, 1.08 to 2.83), with a 
total of 73 deaths, whereas no significant differ-
ence was detected with 194 deaths in the TEXT–
SOFT analysis. The ABCSG-12 trial showed a 
significant improvement in disease-free survival 
among women randomly assigned to receive the 
bisphosphonate zoledronic acid, as compared 
with those who did not receive zoledronic acid. 
TEXT and SOFT did not permit the routine use 
of bisphosphonates, and only a minority of 
women reported bisphosphonate use during ad-
juvant therapy.
In TEXT and SOFT, women had the option of 
receiving adjuvant chemotherapy after discussion 
with their physician. Chemotherapy was not ad-
ministered to 1996 women (43%), and 21% of the 
patients in TEXT who did not receive chemo-
therapy had node-positive disease. Nevertheless, 
the rate of freedom from breast cancer at 5 years 
was more than 97% among women who did not 
receive chemotherapy and were assigned to ex-
emestane plus ovarian suppression (Fig. S2 in the 
Supplementary Appendix). The majority of patients 
were enrolled at BIG centers, where multigene 
assays to assess risk of recurrence were not stan-
dard during the enrollment years. Predominant-
ly on the basis of conventional clinicopathologic 
features, physicians identified a group of premeno-
pausal women with truly endocrine-responsive 
breast cancer who had very good outcomes with-
out adjuvant chemotherapy. These results indi-
cate that at least a proportion of premenopausal 
women who receive a diagnosis of hormone-
receptor–positive breast cancer may have an ex-
cellent prognosis with highly effective adjuvant 
endocrine therapy alone.
For women who receive chemotherapy, the 
timing of the initiation of ovarian suppression is 
worthy of consideration. TEXT and SOFT differed 
with respect to the approach to the initiation of 
ovarian suppression in women who received 
chemotherapy. Patients in TEXT began receiving 
adjuvant ovarian suppression with triptorelin con-
currently with chemotherapy, an average of 1.2 
months after surgery; patients assigned to exemes-
tane plus ovarian suppression had a rate of free-
dom from breast-cancer recurrence at 5 years of 
91.5% (Fig. S3 in the Supplementary Appendix), 
despite the fact that 66% of the women in TEXT 
who received chemotherapy had node-positive 
disease. The early initiation of ovarian suppres-
sion to target the estrogen-receptor pathway con-
currently with chemotherapy deserves further 
investigation.
The SOFT cohort of patients who received che-
motherapy completed all chemotherapy before 
enrollment and initiated protocol-assigned ovari-
an suppression and oral endocrine therapy an 
average of 8 months after surgery, with 4 months 
of adjuvant tamoxifen therapy during the inter-
vening period. This cohort included younger pa-
tients on average — owing to the requirement to 
retain premenopausal status — than did the 
TEXT cohort that received chemotherapy. The 
cohort also had a greater proportion of patients 
with lymph-node–negative disease; this could be 
related in part to physicians’ reluctance, at least 
in some countries, to include high-risk patients 
in a trial considering tamoxifen alone after che-
motherapy. The longer time from diagnosis to 
study entry may account for the higher propor-
tion of breast-cancer recurrences in this cohort, 
as compared with the TEXT cohort that received 
chemotherapy (Fig. S3 in the Supplementary Ap-
pendix).
The adverse-event profiles of exemestane plus 
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ovarian suppression and tamoxifen plus ovarian 
suppression were similar to those seen in post-
menopausal women, and the percentages of ad-
verse events of grade 3 or 4 were similar in the 
two treatment groups. Between-group differ-
ences were observed with respect to specific 
symptoms, but the overall quality-of-life assess-
ment did not favor either treatment. The early 
cessation of all protocol-assigned treatment 
was more frequent among patients who re-
ceived exemestane plus ovarian suppression 
than among those who received tamoxifen plus 
ovarian suppression (16% vs. 11%).
In premenopausal women, an additional ben-
efit of ovarian suppression in women who re-
ceive 5 years of adjuvant tamoxifen, with or 
without chemotherapy, is uncertain. A meta-
analysis of trials that included patients ran-
domly assigned to receive 2 years of a GnRH 
agonist plus tamoxifen versus 2 years of tamoxi-
fen alone showed that adding ovarian suppres-
sion was associated with an estimated 14.5% 
reduction in recurrence (95% CI, −32.7 to 8.6) 
without chemotherapy and an estimated 15.9% 
reduction in recurrence (95% CI, −42.4 to 22.6) 
after chemotherapy.17
We conclude that for premenopausal women 
with hormone-receptor–positive breast cancer, 
adjuvant treatment with ovarian suppression plus 
the aromatase inhibitor exemestane, as compared 
with ovarian suppression plus tamoxifen, pro-
vides a new treatment option that reduces the 
risk of recurrence. Premenopausal women who 
receive ovarian suppression may now benefit from 
an aromatase inhibitor, a class of drugs that 
until now has been recommended only for post-
menopausal women.
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